Moreover, in a longitudinal study, the inconsistent rate of HER2 expression in patients with advanced or recurrent BC was as high as 38%, and more than a third of HER2-0 BC patients exhibited a trend of transformation to HER2-low BC in metastatic lesions [20]. The gene discussed is ERBB2; the disease is breast cancer.